Target intelligence / Profile preview

Peripheral nerve proteins and membranes

Molecular classification
Transmembrane protein, Ig superfamily protein, Fatty acid-binding protein, Structural membrane protein, Membrane lipid component
01

Overview

Peripheral nerve proteins and membranes refer to the ensemble of structural and functional proteins (such as PMP22, P0, and P2) and lipid bilayers that comprise the myelin sheath enveloping axons in the peripheral nervous system. These proteins are crucial for the assembly, stability, and function of the myelin membrane, which enables rapid electrical signal conduction. Mutations in major peripheral nerve proteins can result in hereditary neuropathies such as Charcot-Marie-Tooth disease and other demyelinating disorders. Peripheral nerve membranes also feature specialized transport and adhesion molecules and present unique barriers to drug delivery, making them therapeutic targets in inherited and acquired nerve injuries.

Other names
Peripheral myelin protein 22 (PMP22)Myelin protein P0Peripheral myelin protein 2 (P2)Schwann cell myelin proteinsMyelin sheath proteins
02

Mechanism of action

Mechanism of action can involve stabilization of protein folding (e.g., for PMP22 in CMT), modulation of membrane cholesterol and lipid composition, facilitation of nerve regeneration often via growth factor signaling, and barrier modulation to enhance drug delivery (e.g., via claudin-1 manipulation for analgesics to peripheral nerves).

03

Biological functions

Myelin sheath formation and maintenanceRapid conduction of nerve impulsesMembrane stabilizationSignal transduction (limited/indirect)Cell adhesionMembrane architecture regulation
04

Disease associations

Charcot-Marie-Tooth disease (CMT)Peripheral neuropathy (PN)Autoimmune peripheral nerve injuryGuillain-Barré syndromeGeneral demyelinating neuropathies
05

Safety considerations

Off-target effects leading to demyelinationToxicity from overexpression or mutation (e.g., PMP22 overexpression causes neuropathy)Risk of immune-mediated degradation of myelin proteinsChallenges in achieving selective delivery across blood-nerve barrier
06

Interacting drugs

Compounds to stabilize mutant PMP22

2 more in the full profile.

07

Biomarkers

PMP22 gene expression (for CMT and some peripheral neuropathies)P0 and P2 protein levels (altered in myelin sheath diseases)Heat shock protein levels in peripheral neuropathy

Beyond the preview

Go deeper on Peripheral nerve proteins and membranes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peripheral nerve proteins and membranes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call